Is there a real difference in the safety of infliximab treatment alone and infliximab combined with concomitant immunosuppression? Single centre experience
Abstract
Frequency of severe adverse events was significantly higher in patients treated with combination therapy of infliximab and immunosuppressants then in patients on infliximab monotherapy, while the frequency of acute infusion reactions was similar in both groups.